FDA broadens APDS treatment options - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA broadens APDS treatment options

An 8-patient study evaluated safety and pharmacokinetics in the younger pediatric population.

  • By

  • Kathryn Wighton

  • September 14, 2026

  • 3 min

Share

Clinical Scorecard: FDA broadens APDS treatment options

At a Glance

CategoryDetail
ConditionActivated phosphoinositide 3-kinase delta syndrome (APDS)
Key MechanismsMutations in PIK3CD or PIK3R1 impair immune system function.
Target PopulationPediatric patients aged 4 to 11 years weighing at least 27 kg.
Care SettingClinical treatment for rare genetic disorders.

Key Highlights

  • Leniolisib (Joenja) approved for younger pediatric patients.
  • Efficacy demonstrated in reducing lymph node size and improving B-cell counts.
  • Common adverse effects include abdominal pain and respiratory tract infections.
  • Patients aged 4 to 11 receive weight-based doses of leniolisib.
  • Leniolisib has orphan drug and rare pediatric disease designations.

Guideline-Based Recommendations

Diagnosis

  • Confirm APDS-associated genetic mutations in patients.

Management

  • Administer leniolisib orally twice daily at weight-based doses.

Monitoring & Follow-up

  • Monitor for lymphoproliferation and immunophenotype normalization.

Risks

  • Avoid use in patients with moderate to severe liver impairment.

Patient & Prescribing Data

Pediatric patients aged 4 to 11 years with APDS.

Leniolisib is effective in managing symptoms and improving immune function.

Clinical Best Practices

  • Conduct genetic testing for APDS mutations.
  • Monitor patients for adverse effects during treatment.
  • Adjust dosing based on patient weight.

Related Resources & Content

Original Source(s)

FDA broadens APDS treatment options

  • by Kathryn Wighton

  • September 14, 2026

Related Content

Pediatric abscess incidence may be higher postpandemic

Head and neck abscess incidence was more than 3-fold higher following the pandemic, while patient characteristics and treatment patterns remained largely similar.

Top 10 evidence-based essentials in pediatrics

A structured framework of guidelines, trials, therapies, and clinical tools used in pediatric practice.

FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.